welcome
CNBC

CNBC

Health

Health

Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs

CNBC
Summary
Nutrition label

75% Informative

Novo Nordisk shares rose after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line with expectations.

CEO Lars Fruergaard Jorgensen sees Wegovy supply improving this year , and brushed off fears of company falling behind Eli Lilly .

CagriSema and amycretin are also in focus.

VR Score

83

Informative language

87

Neutral language

56

Article tone

semi-formal

Language

English

Language complexity

47

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links